These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 1859184

  • 1. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.
    Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF.
    Ann Neurol; 1991 May; 29(5):548-55. PubMed ID: 1859184
    [Abstract] [Full Text] [Related]

  • 2. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
    Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF.
    Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
    [Abstract] [Full Text] [Related]

  • 3. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
    Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
    [Abstract] [Full Text] [Related]

  • 4. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.
    McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE.
    Ann Neurol; 1992 Dec 24; 32(6):758-66. PubMed ID: 1471866
    [Abstract] [Full Text] [Related]

  • 5. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
    Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, Valk J, Hommes OR.
    AJR Am J Roentgenol; 1992 Nov 24; 159(5):1041-7. PubMed ID: 1414773
    [Abstract] [Full Text] [Related]

  • 6. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
    Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF.
    Ann Neurol; 1995 May 24; 37(5):611-9. PubMed ID: 7755356
    [Abstract] [Full Text] [Related]

  • 7. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y, Traboulsee A, Petkau AJ, Li D.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [Abstract] [Full Text] [Related]

  • 8. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
    Gonzalez-Scarano F, Grossman RI, Galetta S, Atlas SW, Silberberg DH.
    Ann Neurol; 1987 Mar 25; 21(3):300-6. PubMed ID: 3606036
    [Abstract] [Full Text] [Related]

  • 9. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months.
    Koopmans RA, Li DK, Oger JJ, Kastrukoff LF, Jardine C, Costley L, Hall S, Grochowski EW, Paty DW.
    Ann Neurol; 1989 Aug 25; 26(2):248-56. PubMed ID: 2774512
    [Abstract] [Full Text] [Related]

  • 10. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R, Bagnato F, Nasuelli D, Bastianello S, Bratina A, Locatelli L, Watts K, Finamore L, Grop A, Dwyer M, Catalan M, Clemenzi A, Millefiorini E, Bakshi R, Zorzon M.
    J Neurol Sci; 2004 Aug 30; 223(2):185-93. PubMed ID: 15337621
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
    Arch Neurol; 2005 Dec 30; 62(12):1843-7. PubMed ID: 16344342
    [Abstract] [Full Text] [Related]

  • 12. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
    Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, Truyen L, Lai HM, Rocca MA, Moseley IF, Miller DH.
    Ann Neurol; 1998 Mar 30; 43(3):332-9. PubMed ID: 9506550
    [Abstract] [Full Text] [Related]

  • 13. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

  • 14. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 23; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 15. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis.
    Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G.
    Ann Neurol; 1998 Jun 23; 43(6):809-14. PubMed ID: 9629851
    [Abstract] [Full Text] [Related]

  • 16. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP.
    Mult Scler; 2009 Sep 23; 15(9):1043-7. PubMed ID: 19570818
    [Abstract] [Full Text] [Related]

  • 17. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 23; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 18. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis.
    Narayana PA, Doyle TJ, Lai D, Wolinsky JS.
    Ann Neurol; 1998 Jan 23; 43(1):56-71. PubMed ID: 9450769
    [Abstract] [Full Text] [Related]

  • 19. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint.
    Healy BC, Ikle D, Macklin EA, Cutter G.
    Mult Scler; 2010 Jul 23; 16(7):840-7. PubMed ID: 20530124
    [Abstract] [Full Text] [Related]

  • 20. Automatic detection of gadolinium-enhancing multiple sclerosis lesions in brain MRI using conditional random fields.
    Karimaghaloo Z, Shah M, Francis SJ, Arnold DL, Collins DL, Arbel T.
    IEEE Trans Med Imaging; 2012 Jun 23; 31(6):1181-94. PubMed ID: 22318484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.